The FTC’s second request imposes an additional waiting period of up to 30 days for the agency to review the deal from the time the Novo Nordisk Foundation and Catalent submit the required information.
Watch out, Incyte. Leo Pharma and its JAK inhibitor cream delgocitinib are coming to disrupt the topical atopic dermatitis market, currently inhibited by Incyte’s approved Opzelura. With several ...
ImmunityBio last week won the FDA’s approval for its immunotherapy Anktiva to be used alongside the Bacillus Calmette-Guérin (BCG) vaccine to treat certain patients with bladder cancer. Problem is, ...
It’s been a turbulent few days for GSK’s respiratory business: On Tuesday, the U.S. Federal Trade Commission (FTC) further cracked down on “junk patent listings,” including those related to a quartet ...
During the Q&A portion of Amgen’s quarterly conference call Thursday, eight of the first nine questions were about the company’s investigational efforts in obesity. | The buzz about Amgen’s obesity ...
This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year. Fierce Pharma Senior Writer Kevin Dunleavy ...
Japan's Ono Pharmaceutical will buy kinase inhibitor expert Deciphera for $2.4 billion. Novartis invests further in radiopharmaceuticals with two deals. WuXi Biologics has withdrawn from the 2024 BIO ...
Eli Lilly has a Fever, and the only prescription is a new corporate partnership. | Eli Lilly has a Fever, and the only ...
Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics ...
Moderna gears up for potential RSV vaccine launch this fall after better-than-expected first quarter
With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based ...
With its newly launched predictive analytics platform, Real Chemistry is hoping to “shine a light” on the GLP-1 agonist ...
As AbbVie and Johnson & Johnson’s Imbruvica retreated, AstraZeneca’s Calquence has become the first BTK inhibitor to claim a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results